1. Home
  2. SRI vs IMUX Comparison

SRI vs IMUX Comparison

Compare SRI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stoneridge Inc.

SRI

Stoneridge Inc.

HOLD

Current Price

$6.85

Market Cap

161.7M

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$9.61

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRI
IMUX
Founded
1965
2016
Country
United States
United States
Employees
N/A
66
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
161.7M
152.6M
IPO Year
1997
2013

Fundamental Metrics

Financial Performance
Metric
SRI
IMUX
Price
$6.85
$9.61
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$16.00
$36.00
AVG Volume (30 Days)
205.4K
2.4M
Earning Date
05-01-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
$824,444,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.46
N/A
52 Week Low
$4.16
$0.51
52 Week High
$9.71
$10.91

Technical Indicators

Market Signals
Indicator
SRI
IMUX
Relative Strength Index (RSI) 58.44 85.13
Support Level $6.61 $0.75
Resistance Level $7.45 N/A
Average True Range (ATR) 0.45 0.46
MACD 0.07 1.01
Stochastic Oscillator 69.04 87.07

Price Performance

Historical Comparison
SRI
IMUX

About SRI Stoneridge Inc.

Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: